Abbott has been awarded the CE Mark for its Alinity™ m diagnostics system and assays, the latest in molecular technology to help manage the growing demand for infectious disease testing. Alinity m will facilitate more molecular diagnostic testing in shorter timeframes, while reducing the space and number of laboratory instruments required to conduct large amounts of tests from four to six instruments down to one. Alinity m offers initial assays including virologic testing for HIV-1, HBV and HCV; sexual health-related testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium panel; high-risk HPV testing.
Divisional vice president, research and development, Molecular Diagnostics, John Carrino, said: "To design Alinity m, we spent countless hours with hundreds of lab directors around the world to address the challenges they face, including higher testing volumes, managing complex, labor-intensive processes and doing so with less time and space. Alinity m will dramatically increase efficiency while delivering accurate results that patients and healthcare professionals can trust to help make decisions about their health and treatment."
“CE Mark for Alinity™ m Diagnostics System and Assays for Abbott.“
Martin Obermeier, M.D., CEO, Medical Center for Infectious Diseases, Berlin said: "Molecular laboratories are playing an increasingly important role in providing critical test results, and we're struggling to keep up with demand. Alinity m will significantly improve the way we operate laboratories by letting staff run any sample at any time, without the need to group samples, allowing us to focus on giving physicians the information they need to make accurate, timely clinical decisions."